bacterial vaccines	prevent	bacterial infections
viral vaccines	prevent	viral infections
combined vaccines	reduce	vaccine visits
combined vaccines	improve	compliance
combined vaccines	lower	cost
combined vaccines	increase	coverage
combined vaccines	reduce	adverse events
combined vaccines	maintain	immunogenicity
combined vaccines	contain	antigens
antigens	stimulate	immune response
immune response	includes	antibodies
immune response	includes	T cells
antibodies	neutralize	pathogens
T cells	kill	infected cells
combined vaccines	schedule	immunization schedule
immunization schedule	follow	guidelines
guidelines	issued by	WHO
guidelines	issued by	CDC
WHO	sets	global standards
CDC	sets	national standards
combined vaccines	licensed by	FDA
FDA	approves	vaccine safety
vaccine safety	assessed by	clinical trials
clinical trials	phase	I
clinical trials	phase	II
clinical trials	phase	III
clinical trials	phase	IV
phase III	confirms	efficacy
phase IV	monitors	post‑marketing safety
combined vaccines	contain	adjuvants
adjuvants	enhance	immune response
adjuvants	include	aluminum salts
adjuvants	include	MF59
MF59	is	oil‑in‑water emulsion
combined vaccines	use	preservative
preservative	is	thimerosal
thimerosal	removed	from	many vaccines
combined vaccines	are	injectable
injectable	route	intramuscular
injectable	route	subcutaneous
combined vaccines	can be	oral
oral	route	gut immunity
gut immunity	protects	enteric pathogens
combined vaccines	reduce	disease burden
disease burden	measured by	DALYs
DALYs	calculated by	WHO
combined vaccines	lower	hospitalization rates
hospitalization rates	affect	healthcare costs
healthcare costs	impact	payer budgets
payer budgets	influence	reimbursement
reimbursement	determined by	CMS
CMS	sets	payment rates
payment rates	affect	provider behavior
provider behavior	influences	vaccine uptake
vaccine uptake	predicts	herd immunity
herd immunity	reduces	transmission
transmission	measured by	R0
R0	influenced by	vaccine coverage
vaccine coverage	reported by	national surveys
national surveys	conducted by	NIS
NIS	collects	immunization data
immunization data	used for	surveillance
surveillance	detects	outbreaks
outbreaks	trigger	emergency use
emergency use	authorized by	WHO
WHO	issues	emergency use listing
emergency use listing	allows	rapid deployment
rapid deployment	requires	cold chain
cold chain	maintained by	logistics
logistics	managed by	health ministries
health ministries	coordinate	vaccination campaigns
vaccination campaigns	target	high‑risk groups
high‑risk groups	include	children
high‑risk groups	include	elderly
high‑risk groups	include	immunocompromised
immunocompromised	may need	alternative schedules
alternative schedules	involve	booster doses
booster doses	improve	long‑term immunity
long‑term immunity	measured by	serology
serology	tests	antibody titers
antibody titers	correlate with	protection
protection	reduces	mortality
mortality	tracked by	vital statistics
vital statistics	reported to	CDC
CDC	publishes	vaccine effectiveness
vaccine effectiveness	informs	policy
policy	guides	funding
funding	supports	research
research	leads to	new vaccine candidates
new vaccine candidates	undergo	preclinical studies
preclinical studies	use	animal models
animal models	predict	human response
human response	assessed by	immunogenicity
immunogenicity	assessed by	ELISA
ELISA	measures	antibody levels
antibody levels	predict	neutralization
neutralization	measured by	plaque reduction
plaque reduction	indicates	efficacy
efficacy	validated by	real‑world studies
real‑world studies	provide	safety data
